HIV-1 infection remains non-curative due to the latent reservoir, primarily a small pool of
resting memory CD4+ T cells bearing replication-competent provirus. Pharmacological …

Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of
immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however …

Simple Summary Immunotherapy-based treatments have brought many new options in the
treatment of multiple myeloma; still, the disease will inevitably relapse as it remains …

With the incorporation of novel agents in earlier lines of therapy, an increasing number of
multiple myeloma patients are refractory to traditional classes of drugs. Selinexor in …

目的: 观察塞利尼索治疗复发难治多发性骨髓瘤的疗效及不良反应. 方法: 回顾性分析河南省肿瘤
医院2021 年6 月—2022 年6 月采用塞利尼索治疗的10 例复发难治多发性骨髓瘤患者的临床 …

Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …

Expert clinical framework report: Management of adverse events related to novel therapies for
relapsed/refractory multiple myeloma (RRMM) | Canadian Hematology Today Skip to main …

Efficacy observation of selinexor-based regimen in the treatment of 10 patients with relapsed/refractory
multiple myeloma Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …